Arylesterase Assay Kit


Paraoxonase-1 (PON1) s an hgh densty lpoproten (HDL)-assocated enzyme wth antoxdant and antatherogenc functons, protectng lpoprotens aganst oxdatve modficaton.  It also catalyzes the hydrolyss of organophosphates such as paraoxon and aromatc carboxylc acd esters of fatty acds. It has been shown that serum paraoxonase actvty decrease n dabetes melltus, coronary artery dsease, hypercholesterolaema, ron deficcency anemma, hepatts, crrhoss, prostate cancer, tuberculoss and nfammmatons.  

 

Paraoxonase-1 (PON1) s an hgh densty lpoproten (HDL)-assocated enzyme wth antoxdant and antatherogenc functons, protectng lpoprotens aganst oxdatve modficaton.  It also catalyzes the hydrolyss of organophosphates such as paraoxon and aromatc carboxylc acd esters of fatty acds. It has been shown that serum paraoxonase actvty decrease n dabetes melltus, coronary artery dsease, hypercholesterolaema, ron deficcency anemma, hepatts, crrhoss, prostate cancer, tuberculoss and nfammmatons.  
 
PON1, present n the sample, hydrolyses phenyl acetate to ts products whch are phenol and acetc acd. The produced phenol s colormetrcally measured va oxdatve couplng wth 4-amnoantpyrne and potassum ferrcyande. Nonenzymatc hydrolyss of phenyl acetate was subtracted from the total rate of hydrolyss. The molar absorptvty of colored complex s 4000 M -1 cm-1 and one unt of arylesterase actvty s equal to 1 mmol of phenyl acetate hydrolyzed per lter per mnute at 37oC.

[PDF] Serum paraoxonase, arylesterase activity and oxidative status in patients with obstructive sleep apnea syndrome (OSAS)

E Baysal, S Taysi, N Aksoy, M Uyar… - Eur Rev Med …, 2012 - europeanreview.org
… increase at 270 nm at 37°C. Enzymatic activity was calculated from the molar absorptivity
coefficient of the pro- duced phenol, which was 1,310 M−1 cm−1. One unit of arylesterase activity
was … The Rel Assay (Rel Assay®, Diagnostics kits, Mega Tıp, Gaziantep, Turkey) was used …  Cited by 26 Related articles All 5 versions [PDF] researchgate.net

[HTML] The effect of date seed (Phoenix dactylifera) extract on paraoxonase and arylesterase activities in hypercholesterolemic rats

MR Takaeidi, A JahangiriMJ Khodayar… - … journal of natural …, 2014 - ncbi.nlm.nih.gov
… acid (Merck, Germany) were used. Paraoxonase, arylesterase and antioxidant activity
were measured using commercially available kits (Rel Assay Diagnostics®, MEGA
TIP San, Turkey). DSE and atorvastatin were diluted in …  Cited by 17 Related articles All 11 versions

[HTML] Total serum oxidant/antioxidant status and arylesterase activity in recurrent aphthous stomatitis

G Akoglu, A Metin, F Kilinc, SD Pektas… - Annals of …, 2013 - synapse.koreamed.org
… Measurement of serum PON1 arylesterase activities. Serum PON1 ARES activity
was measured by using commercially available kits (Rel Assay Diagnostics, Mega
Tıp, Gaziantep, Turkey). Serum ARES activity was determined …  Cited by 16 Related articles All 27 versions [HTML] eje-online.org

The relationship between oxidative stress and autoimmunity in Hashimoto's thyroiditis

I Ates, FM Yilmaz, M Altay, N Yilmaz, D Berker… - European journal of …, 2015 - EFES
… No: RL0031, LOT No: JE14028P) with %CV, five, and linearity, 0–750 U/l. Serum
arylesterase levels were measured with the colorimetric method using a commercial
kit (Rel Assay Diagnostics, REF. No: RL0055, LOT No: JR13017AR) …  Cited by 17 Related articles All 5 versions

Relationship between oxidative stress parameters and asymptomatic organ damage in hypertensive patients without diabetes mellitus

I Ates, N Ozkayar, C Topcuoglu… - Scandinavian …, 2015 - Taylor & Francis
… Serum arylesterase level was measured with a com- mercial kit (Rel Assay Diagnostics, Turkey,
REF No: RL0055, LOT No … Arylesterase 0.994 0.990 0.998 0.033 … 24-h SBP, 24-h DBP, use of
antihypertensive drugs, lipid parameters, OSI, total thiol, PON1, ARES, and PON1/HDL …  Cited by 12 Related articles All 3 versions

Evaluation of oxidative stress, the activities of paraoxonase and arylesterase in patients with subclinic hypothyroidism

E Cebeci, FA Oner, M Usta - Acta Bio Medica Atenei …, 2012 - mattioli1885journals.com
… Measurement of PON 1 Arylesterase Activity PON 1 arylesterase activity of the serum
samples was measured using full-automatized method devel- oped by Rel Assay
Diagnostics® (Mega Tıp, Gaziantep, Turkey. According …  Cited by 12 Related articles All 4 versions [HTML] nih.gov

[HTML] The oxidant and antioxidant status in pityriasis rosea

S Emre, G Akoglu, A Metin, DD Demirseren… - Indian journal of …, 2016 - ncbi.nlm.nih.gov
… Measurement of serum PON1/arylesterase activities. Serum PON1/arylesterase
(ARES) activity was measured by using commercially available kits (Rel Assay
Diagnostics, Mega Tύp, Gaziantep, Turkey). Serum ARES activity …  Related articles All 9 versions

[PDF] Comparison of the Paraoxonase and Arylesterase Activities in Follicle Fluid of Females with PCOS in ICSI Cycle

Ü GÖKTOLGA, HO TOPÇU, Ö ÇINAR, S IŞIKOĞLU… - 2017 - tjrms.org
… Reagents were commercially ob- tained from Rel Assay Diagnostics® (Gaziantep, Turkey) … TAS:
Total antioxidant status, TOS: Total oxidant status, PON: Paraoxonase, SPON: Sti- mulated
paraoxonase, ARESArylesterase, OSI: Oxidative stress index, OSI = [TOS µmol/l/TAC …  Related articles All 2 versions [HTML] tandfonline.com

Paraoxonase and arylesterase activities in adults with vitamin B12 deficiency

T Guney, M AlisikA AlkanA Basturk, S Akinci… - Redox …, 2016 - Taylor & Francis
… The activity of ARES was measured using an ARES assay kit, and the activity of PON1 was
measured using a fully automated PON activity measurement kit (Rel Assay Diagnostics,
Gaziantep, Turkey) with a Cobase 501 automated analyzer (Roche) in the … ARESarylesterase …  Cited by 1 Related articles All 3 versions


Buffered Diluent1 x 30 ml
Reagent 2 - Substrate1 x 8 ml
Reagent 3 - Chromogen1 x 15 ml


1. Suchocka Z, Swatowska J, Pachecka J, Suchocka P; RP-HPLC determnaton of Paraoxonase actvty n human blood serum; J of Pharmaceutcal and Bomedcal Analyss  2006;  42:113-119

2. Marchegan F, Marra M, Olver F, Cardell M, James RW, Boem M, Francesch C.   Paraoxonase 1: genetcs and actvtes durng agng. Rejuvenaton Res. 2008 Mar;11(1):113-27.

3. Hofer  Hofer SE, Bennetts B, Chan AK, Holloway B, Karschmkus C, Jenkns AJ, Slnk M, Donaghue KC. Assocaton between PON 1 polymorphsms, PON actvty and dabetes complcatons. J Dabetes Complcatons. 2006 20(5):322 -8.

4. Mackness MI, Harty D, Bhatnagar D, Wnocour PH, Arrol S, Ishola M, Durrngton P N. Serum paraoxonase actvty n famlal hypercholesterolaema and nsuln-dependent dabetes melltus. Atheroscleross. 1991; 86(2-3):193-9. 

5. Horoz M, Aslan M, Selek S, Koylu AO, Bolukbas C, Bolukbas FF, Celk H, Erel O.   PON1 status n haemodalyss p atents and the mpact of hepatts C nfecton. Cln Bochem. 2007;40(9-10):609-14.

6. Gur M, Aslan M, Yldz A, Demrbag R, Ylmaz R, Selek S, Erel O, Ozdogru I.  Paraoxonase and arylesterase actvtes n coronary artery dsease. Eur J Cln Invest. 2006 Nov;36(11):779-87.

7. Aslan M, Koseck M, Horoz M, Selek S, Celk H, Erel O. Assessment of paraoxonase and arylesterase actvtes n patents wth ron deficcecy aneema. Atherosclerooss. 2007 Apr;191(2):397 -402. 8. Aslan M, Nazlgul Y, Horoz M, Bolukbas C , Bolukbas FF, Gur M, Celk H, Erel O.  Serum paraoxonase -1 actvty n Helcobacter pylor nfected subjects. Atheroscleross. 2008 Jan;196(1):270-4.